Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells

Silva, J M; Rodríguez, Rafael Gómez; García, José M.; Muñoz, Concepción; Silva, J; Domínguez, Gemma; Provencio, Mariano; España, Pilar; Bonilla, Félix

doi:10.1136/gut.50.4.530

Cited by 134 publications

(127 citation statements)

References 29 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In breast cancer exRNAs have been documented by a number of research groups [63,[96][97][98]. We present the most documented studies on cell-free exRNAs and CTC associated RNAs.…”

Section: Extracellular Rnas and Ctcs Associated Rnas In Breast Cancermentioning

confidence: 99%

“…Initially, Silva et al [96] identified CK19 mRNA in plasma of breast cancer patients (49%) in comparison to healthy controls (20%). On evaluation of clinicopathological parameters (including patient age, tumor size, histopathological type and stage, lymph node metastases, ER and PR status, proliferative index) with molecular data, two parameters (tumor size and proliferative index as determined by Ki-67 IHC) were associated with the presence of plasma CK19 mRNA.…”

Section: Cytokeratin 19mentioning

confidence: 99%

See 1 more Smart Citation

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Friel

Corcoran

Crown

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement-which in itself may have detrimental effects in terms of stimulating cancer progression/metastases-minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.

show abstract

“…In breast cancer exRNAs have been documented by a number of research groups [63,[96][97][98]. We present the most documented studies on cell-free exRNAs and CTC associated RNAs.…”

Section: Extracellular Rnas and Ctcs Associated Rnas In Breast Cancermentioning

confidence: 99%

Section: Cytokeratin 19mentioning

confidence: 99%

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Friel

Corcoran

Crown

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…One area of intense breast cancer research has been in assessing prognostic factors of patient outcomes, and several molecular markers have been evaluated in association with established histologic and clinical prognostic parameters of breast cancer (Honkoop et al, 1998;Rizzieri et al, 1999;Sabbatini et al, 2000;Silva et al, 2001).…”

mentioning

confidence: 99%

Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer

et al. 2003

View full text Add to dashboard Cite

HMGI-C belongs to the high-mobility-group-protein (HMG) family of architectural transcription factors and considerable interest has recently been shown in its expression in neoplastic tissues and apparent involvement in tumorigenesis. We could previously demonstrate an expression of HMGI-C mRNA in the peripheral blood of breast cancer patients for the first time. In this prospective study, we evaluated the independent prognostic power of HMGI-C mRNA expression in the peripheral blood of an unselected cohort of 69 patients with metastatic breast cancer using a hemi-nested reverse transcriptase polymerase chain reaction (RT -PCR) followed by sequence analysis of the resulting PCR products. Multivariate analysis was performed using the Cox regression model. HMGI-C mRNA was detected in peripheral blood from 21 out of 69 (30%) patients with metastatic breast cancer. Median survival was 15.9 months in patients expressing HMGI-C, while in the group of patients without HMGI-C expression the median survival had not been reached yet after a median follow-up of 24.7 months and 85.4% were still alive in this group. Disease-specific survival was significantly worse for patients positive for HMGI-C in comparison to those not expressing HMGI-C (P ¼ 0.0001). In a multivariate regression analysis, HMGI-C remained an independent prognostic factor for overall survival (P ¼ 0.001) besides oestrogen receptor status (P ¼ 0.024) and presence of metastases in liver and lungs (P ¼ 0.029). HMGI-C expression in the peripheral blood of patients with metastatic breast cancer is a powerful independent indicator for poor overall survival and this is the first study to demonstrate its prognostic relevance in univariate and multivariate analysis.

show abstract

“…The detection of epithelial tumour RNA in plasma from colon cancer patients is associated with advanced stages and circulating tumour cells (Silva et al, 2002). Two different studies regarding patients with head and neck squamous cell carcinoma (HNSCC) and OSCC, respectively, found that serum p53 antibody is a significant prognostic factor for nodal metastasis (Chow et al, 2001;Hofele et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples

et al. 2003

View full text Add to dashboard Cite

The presence of an oral squamous cell carcinoma (OSCC) may be associated with increased urinary excretion of the markers of collagen degradation, hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). We investigated the possibility of these markers predicting the presence of active disease. Patients from a current study on HP and LP were included as follows: Group 1a (OSCC with confirmed mandibular bony infiltration, n ¼ 12), group 1b (group 1a patients 46 months after successful treatment), group 2a (OSCC without evidence of mandibular bone infiltration, n ¼ 8), group 2b (group 2a patients 46 months after successful treatment), group 3a (recurrent OSCC, n ¼ 8), group 3b (group 3a patients 46 weeks later, symptoms unchanged) and group 4 (control group, n ¼ 74). Tissue samples from tumour tissue and adjacent healthy mucosa were additionally investigated for HP and LP concentrations (n ¼ 8). The decrease in the urinary concentrations of HP and LP was statistically significant between groups 1a and 1b (Po0.001 for HP and LP), but not between groups 2a and 2b (P ¼ 0.07 for HP and LP), while values in groups 1b and 2b were within the normal range. When comparing groups 3a and 3b, a significant increase was observed for LP (P ¼ 0.050), but not HP (P ¼ 0.208). In conclusion, successful treatment of OSCC with bony involvement may be associated with a reduction of urinary HP and LP, whereas ongoing disease may result in an increase of LP. HP and LP may both be useful markers of tumour progression in patients with OSCC. British Journal of Cancer (2003) Hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) are two nonreducible crosslinks of mature collagen, which are formed by a sequence of post-translational modifications. HP is a derivative of three residues of hydroxylysine, and is present in virtually all mature tissues (tendon, vessel wall, cartilage, dentine and bone). LP is a derivative of two residues of hydroxylysine and one residue of lysine, and is found primarily in dentine and bone (Body and Delmas, 1992;Eyre, 1992;Miyamoto et al, 1994;Acil et al, 1996Acil et al, , 2002aPapatheofanis, 1997;Tamada et al, 2001;Jepsen et al, 2003; Springer et al, 2003a, b).It has been suggested that the detection of LP in the serum or urine may be a helpful marker in establishing and possibly quantifying bone matrix resorption (Body and Delmas, 1992;Miyamoto et al, 1994;Vinholes et al, 1996;Papatheofanis, 1997;Tamada et al, 2001;Springer et al, 2003a). In a previous study, we were able to assess the range and upper limit (HP max and LP max ) of normal values. We were able to show that the measurement of LP in the urine was able to separate a group of patients with oral squamous cell carcinoma (OSCC) with bone infiltration from patients with OSCC without bone infiltration with a sensitivity of 100% and a specificity of 100% (Springer et al, 2003a). In that paper, we suggested that when the level of LP exceeds LP max in a patient with a confirmed OSCC, bony invasion by the malignant process is highly likely and further inve...

show abstract

Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells

Cited by 134 publications

References 29 publications

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer

Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples

Contact Info

Product

Resources

About